Fochon Pharmaceuticals Receives CFDA Approval for Clinical Trials of Innovative Medicine to Treat Solid Tumors

Fochon Pharmaceuticals Receives CFDA Approval for Clinical Trials of Innovative Medicine to Treat Solid Tumors

Fochon Pharmaceuticals receives CFDA approval for clinical trials of the innovative drug FCN-437 capsule, which is intended to treat solid tumors.

Until December 2017, Fochon receives the investment with approximately RMB 28 million on R&D for FCN-437.

Until January 23th, 2018, there is no medicine with independent intellectual property right launched in China (excluding Hong Kong, Macau and Taiwan) with the same targeted therapy as FCN-437.

In 2016, the global sales of similar medicine amounted to about $2.1 billion.